Waiv, a Paris-based developer of AI-powered precision oncology testing technology, announced it has raised $33 million in financing to accelerate global deployment of its AI precision testing platform and expand its clinical-grade diagnostic offerings.
The funding round was co-led by OTB Ventures and Alpha Intelligence Capital, with participation from Serena Data Ventures, Karista, and SistaFund. The investment coincides with Waiv’s spinout from AI biotech company Owkin, where the team previously operated as Owkin Dx.
Waiv is focused on using artificial intelligence to transform how cancer diagnostics are performed. Its platform analyzes routinely generated digital histopathology slides and multimodal clinical data to identify biological signals that can guide treatment decisions, enabling faster and more accurate patient stratification and therapy selection.
The company’s technology is already being used in clinical settings through several products, including RlapsRisk BC for breast cancer risk assessment, MSIntuit Suite for microsatellite instability detection, and BRCAura, an AI-based pre-screen test for identifying germline BRCA mutations from pathology slides.
Waiv’s platform combines large-scale multimodal datasets with proprietary AI models and clinical validation capabilities in a single integrated stack. It also includes Destra, a digital pathology platform designed to integrate directly into existing laboratory and pathology workflows, allowing clinicians and labs to run Waiv’s diagnostic tests without changing their operational systems.
The company is supported by an extensive research data network, including the PortrAIt consortium, a large multi-institutional initiative across Europe focused on advancing AI-driven pathology research.
Waiv has also formed partnerships with global pharmaceutical companies to support drug development and biomarker discovery. These collaborations include work with AstraZeneca on an AI-driven gBRCA pre-screen test for breast cancer and with MSD to develop AI-powered diagnostics to identify microsatellite instability–enriched patient populations.
According to the company, the new capital will be used to expand its portfolio of multimodal precision tests, deepen integrations with pharmaceutical research and development pipelines, and expand market access globally so more laboratories and healthcare providers can adopt its diagnostic technologies.
KEY QUOTES
“Precision medicine only works when patients can be reliably matched to the therapies most likely to benefit them. This remains very complex to achieve. Waiv brings the scalability and speed of AI to oncology testing, while enabling drug developers to access insights that were previously out of reach. Our goal is to make accurate AI-enabled precision testing the global standard.”
Meriem Sefta, CEO And Co-Founder, Waiv
“Waiv is bringing a level of technological advancement and maturity that oncology has been waiting for. Their AI tech stack, built on advanced foundation models, can convert routine pathology slides into high-resolution maps of disease biology, providing both generalizability and scalability across different clinical settings. We are excited to partner with a world-class team and support Waiv as they set a new standard for how oncology is understood and treated.”
Karol Szubstarski, Partner, OTB Ventures
“What sets Waiv apart is not just its technology, but its proven clinical impact across applications from outcome prediction to biomarker detection. With exceptional scientific depth, a track record of real-world impact, and strong revenue-generating partnerships with global pharma, Waiv exemplifies how AI is set to revolutionize healthcare driving highly personalized, efficient, and outcome-focused medicine.”
Arnaud Barthélémy, Partner, Alpha Intelligence Capital
“We’ve collaborated closely with the team behind Waiv for years, and with their launch, co-developed tools like RlapsRisk BC for breast cancer can now reach a wider clinical audience, which will be a major win for patients.”
Fabrice André, MD, PhD, Director Of Research, Gustave Roussy
